<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Terazosin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01162</strong>&#160; (APRD00667)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (<span class="caps">BPH</span>). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01162/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01162/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01162.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01162.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01162.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01162.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01162.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01162">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Terazosina</td><td>Spanish</td><td>INN</td></tr><tr><td>Terazosine</td><td>French</td><td>INN</td></tr><tr><td>Terazosinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Terazosin Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000326/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000326/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: IWSWDOUXSCRCKW-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 423.167332052</li>
              <li>Average Mass: 423.894</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000326">DBSALT000326</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Blavin</td><td>Baliarda (Argentina)</td></tr><tr><td>Flumarc</td><td>Raffo (Argentina)</td></tr><tr><td>Fosfomic</td><td>Finadiet (Argentina)</td></tr><tr><td>Heitrin</td><td>Abbott (Germany; discontinued)</td></tr><tr><td>Hytrin</td><td>Abbott</td></tr><tr><td>Hytrinex</td><td>Amdipharm (Sweden)</td></tr><tr><td>Itrin</td><td>Keryos (Italy)</td></tr><tr><td>Urodie</td><td>Keryos (Italy)</td></tr><tr><td>Vicard</td><td>Amdipharm (Austria)</td></tr><tr><td>Zayasel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/adrenergic-alpha-1-receptor-antagonists">Adrenergic alpha-1 Receptor Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>63590-64-7</td></tr><tr><th>Weight</th><td>Average: 387.4329<br>Monoisotopic: 387.190654313</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>VCKUSRYTPJJLNI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Quinazolines</td></tr><tr><th>Direct parent</th><td>Quinazolinamines</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Aminopyrimidines and Derivatives; Primary Aromatic Amines; Diazinanes; Piperazines; Oxolanes; Tetrahydrofurans; Tertiary Carboxylic Acid Amides; Tertiary Amines; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; aminopyrimidine; piperazine; 1,4-diazinane; pyrimidine; benzene; primary aromatic amine; tetrahydrofuran; oxolane; tertiary carboxylic acid amide; carboxamide group; tertiary amine; enolate; polyamine; ether; carboxylic acid derivative; carboxylic acid; primary amine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of symptomatic BPH and mild to moderate hypertension.</td></tr><tr><th>Pharmacodynamics</th><td>Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an &#945;-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.</td></tr><tr><th>Mechanism of action</th><td>In general, &#945;<sub>1</sub>-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. &#945;<sub>1</sub>-Receptors are 7-transmembrane domain receptors coupled to G proteins, G<sub>q/11</sub>. Three &#945;<sub>1</sub>-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: &#945;<sub>1A</sub> (chromosome 8), &#945;<sub>1B</sub> (chromosome 5), and &#945;<sub>1D</sub> (chromosome 20). Terazosin is the first &#945;<sub>1</sub>-receptor antagonist to demonstrate selectivity for the &#945;<sub>1A</sub>-receptor.  All three receptor subtypes appear to be involved in maintaining vascular tone. The &#945;<sub>1A</sub>-receptor maintains basal vascular tone while the &#945;<sub>1B</sub>-receptor mediates the vasocontrictory effects of exogenous &#945;<sub>1</sub>-agonists. Activation of &#945;<sub>1</sub>-receptors activates G<sub>q</sub>-proteins, which results in intracellular stimulation of phospholipases C, A<sub>2</sub>, and D. This results in mobilization of Ca<sup>2+</sup> from intracellular stores, activation of mitogen-activated kinase and PI<sub>3</sub> kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting &#945;<sub>1A</sub>-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.</td></tr><tr><th>Absorption</th><td>Essentially completely absorbed in man (90% bioavailability).</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>90-94%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.</p></td></tr><tr><th>Route of elimination</th><td>Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.</td></tr><tr><th>Half life</th><td>12 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=259.3mg/kg (IV in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9646</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8868</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.698</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5666</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8619</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6319</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8864</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8032</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7753</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9435</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9628</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9492</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7905</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.901</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5943
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.906
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9785
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2262 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8368
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8204
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories pharmaceutical products div</li>
<li>Apotex inc</li>
<li>Cadista pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan laboratories inc</li>
<li>Mylan technologies inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.cadista.com">Cadista Pharmaceuticals Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.intaspharma.com">Intas Pharmaceuticals Ltd.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>1 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>10 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>2 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>1 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00346">Alfuzosin</a></td><td>Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01143">Amifostine</a></td><td>Terazosin may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Terazosin should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. </td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB04846">Celiprolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB04861">Nebivolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00073">Rituximab</a></td><td>Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab.</td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>Increased risk of hypotension. </td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Tadalafil may enhance the hypotensive effect of Terazosin. Monitor for hypotension during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Terazosin, may occur. Monitor for hypotension during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>